Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 388

1.

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.

Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J.

J Gastroenterol Hepatol. 2006 Feb;21(2):406-12.

PMID:
16509866
[PubMed - indexed for MEDLINE]
2.

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta E Vale A, Wintfeld N, Green J.

J Hepatol. 2004 Apr;40(4):675-81.

PMID:
15030985
[PubMed - indexed for MEDLINE]
4.

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.

Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P; PEGASYS Study NR16071 Investigator Group.

Gastroenterology. 2004 Dec;127(6):1724-32.

PMID:
15578510
[PubMed - indexed for MEDLINE]
5.

The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.

Hornberger J, Farci P, Prati D, Zeuzem S, Green J, Patel KK.

J Viral Hepat. 2006 Jun;13(6):377-86.

PMID:
16842440
[PubMed - indexed for MEDLINE]
6.
7.

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.

Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A; Austrian Hepatitis Study Group.

J Hepatol. 2006 Feb;44(2):275-82. Epub 2005 Nov 7.

PMID:
16338019
[PubMed - indexed for MEDLINE]
8.

Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.

Perrillo R, Rothstein KD, Rubin R, Alam I, Imperial J, Harb G, Hu S, Klaskala W.

J Viral Hepat. 2004 Mar;11(2):157-65.

PMID:
14996351
[PubMed - indexed for MEDLINE]
9.

Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M, Kilani A, Kochlef A, Kharrat J, Ghorbel A.

Tunis Med. 2008 Apr;86(4):341-5.

PMID:
19476135
[PubMed - indexed for MEDLINE]
10.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
[PubMed - indexed for MEDLINE]
11.

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

Perry CM, Jarvis B.

BioDrugs. 2002;16(3):213-7. Review.

PMID:
12102649
[PubMed - indexed for MEDLINE]
12.

Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.

Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S.

Liver Int. 2008 Jan;28(1):61-71. Epub 2007 Oct 25.

PMID:
17971091
[PubMed - indexed for MEDLINE]
13.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
14.

Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.

J Gastroenterol Hepatol. 2007 May;22(5):669-75.

PMID:
17444854
[PubMed - indexed for MEDLINE]
15.

Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.

Berg C, Goncales FL Jr, Bernstein DE, Sette H Jr, Rasenack J, Diago M, Jensen DM, Graham P, Cooksley G.

J Viral Hepat. 2006 Jul;13(7):435-40.

PMID:
16792536
[PubMed - indexed for MEDLINE]
16.

A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.

Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y.

Acta Gastroenterol Belg. 2007 Apr-Jun;70(2):177-87.

PMID:
17715631
[PubMed - indexed for MEDLINE]
17.

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.

Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O.

Scand J Gastroenterol. 2007 Feb;42(2):247-55.

PMID:
17327945
[PubMed - indexed for MEDLINE]
18.

Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.

Keam SJ, Cvetković RS.

BioDrugs. 2009;23(1):63-8. doi: 10.2165/00063030-200923010-00007. Review.

PMID:
19344193
[PubMed - indexed for MEDLINE]
19.

Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.

Basso M, Giannini EG, Torre F, Blanchi S, Savarino V, Picciotto A.

Hepatology. 2009 May;49(5):1442-8. doi: 10.1002/hep.22810.

PMID:
19350657
[PubMed - indexed for MEDLINE]
20.

Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy.

Su WP, Peng CY, Lai HC, Liao KF, Huang WH, Chuang PH, Chen CB, Jeng LB.

Hepatogastroenterology. 2009 May-Jun;56(91-92):798-801.

PMID:
19621705
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk